N@N

Accelrys to Showcase New Biotherapeutics Research Tools in Discovery Studio(R) at CHI's PepTalk 2010 Conference

^{Published on 2010-01-07 13:20:09 - Market Wire}
 

SAN DIEGO, CA--(Marketwire - January 7, 2010) - Accelrys, Inc. (NASDAQ: [ ACCL ]), a leading provider of scientific business intelligence software and services, will participate in the [ CHI PepTalk 2010 Conference ] being held at the Hotel Del Coronado in San Diego, CA from January 11-15, 2010. Accelrys Protein Engineering and Antibody Modeling experts will showcase new features and enhancements found in Accelrys Discovery Studio 2.5.5 that both enable and improve the modeling of antibody structure and function. The advanced computational technology supported by the Discovery Studio environment allows scientists to explore the antibody landscape in silico prior to costly experimental implementation, thus greatly reducing the time and expense involved in bringing such products to market, while increasing scientific productivity. Accelrys will be exhibiting the latest release of Accelrys Discovery Studio in booth #32.

On Monday, January 11th at 3:35 pm, Dr. Shikha Varma-O'Brien of Accelrys will present "Modeling the 3-Dimensional Structures of Antibody and their Interaction Interface to Antigen." She will discuss and demonstrate how Accelrys Discovery Studio not only contains the tools necessary to construct modeling framework from antibodies, but also enables structure based prediction of antibodies by physical properties with the goal of uncovering novel antibody designs.

Visit [ Accelrys at PepTalk ] for more information.

About Accelrys, Inc.

Headquartered in San Diego, California, Accelrys [ develops scientific business intelligence ] software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products [ industries ]. Customers include many Fortune 500 companies and other commercial entities, as well as academic and government entities. Accelrys has a vast portfolio of computer-aided design modeling and simulation offerings which assist customers in conducting scientific experiments 'in silico' in order to reduce the duration and cost of discovering and developing new drugs and materials. Its [ scientific business intelligence platform ] underlies the company's computer-aided design modeling and simulation offerings. The Accelrys platform can be used with both Accelrys and competitive products, as well as with customers' proprietary predictive science products. Its flexibility, ease-of-use and advanced chemical, text, image analysis and reporting capabilities enable customers to mine, aggregate, analyze and report scientific data from disparate sources, thereby better utilizing scientific information within their organizations. For more information about Accelrys, visit [ http://accelrys.com/ ]